These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1834118)

  • 1. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO).
    Calero F; Asins-Codoñer E; Jimeno J; Rodriguez Escudero F; Mendaña J; Iglesias J; Matía F; Armas A; Díaz-Castellanos R; Garzón J
    Eur J Cancer; 1991; 27(7):864-6. PubMed ID: 1834118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent epirubicin in squamous cell cervical cancer. A phase II trial.
    Calero F; Rodriguez-Escudero F; Jimeno J; Mendaña J; Iglesias J; Murillo F; Ugalde F; Armas A; Rementeria A; Asins J
    Acta Oncol; 1991; 30(3):325-7. PubMed ID: 2036241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.
    Campora E; Vidali A; Mammoliti S; Ragni N; Conte PF
    Eur J Gynaecol Oncol; 1990; 11(3):181-3. PubMed ID: 2209636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
    Feld R; Wierzbicki R; Walde PL; Shepherd FA; Evans WK; Gupta S; Shannon P; Lassus M
    J Clin Oncol; 1992 Feb; 10(2):297-303. PubMed ID: 1310105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer.
    Calero F; Jimeno J; Rodríguez-Escudero F; Asins Codoner J; Mendana J; Iglesias J; Murillo F; Ugalde F; Armas A; Rementería A
    Eur J Gynaecol Oncol; 1992; 13(1):83-9. PubMed ID: 1547798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study with high doses of epirubicin in patients with advanced rectal cancer.
    Alberola V; García Conde J; Jimeno J; Fernandez Martos C; Herranz C; Macheng I; Centelles M; Sánchez J
    Tumori; 1990 Oct; 76(5):503-4. PubMed ID: 2256199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas.
    Wils J; Bleiberg H; Blijham G; Dalesio O; Duez N; Lacave A; Splinter T
    Eur J Cancer Clin Oncol; 1985 Feb; 21(2):191-4. PubMed ID: 3857181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM; Chen CH; Chang JW; Tsao TC
    Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of epirubicin in advanced soft tissue sarcoma.
    Chevallier B; Montcuquet P; Fachini T; Nguyen Bui B; Kerbrat P; Bastit P; Vo Van ML
    Bull Cancer; 1990; 77(10):991-5. PubMed ID: 2249019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
    Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
    Topham C; Glees J; Coombes RC
    Oncology; 1993 Apr; 50 Suppl 1():78-80. PubMed ID: 8483561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
    Cho EK; Lee WK; Im SA; Lee SN; Park SH; Bang SM; Park DK; Park YH; Shin DB; Lee JH
    Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
    Park SH; Park YH; Lee JN; Bang SM; Cho EK; Shin DB; Lee JH
    Cancer; 2006 Jan; 106(2):361-5. PubMed ID: 16342166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Papadimitriou CA; Bafaloukos D; Bozas G; Kalofonos H; Kosmidis P; Aravantinos G; Fountzilas G; Dimopoulos MA;
    Gynecol Oncol; 2008 Jul; 110(1):87-92. PubMed ID: 18455782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medrogestone therapy in advanced endometrial adenocarcinoma.
    Waterman EA; Benson RC
    Obstet Gynecol; 1967 Nov; 30(5):626-34. PubMed ID: 4167865
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.
    van der Burg ME; Bolis G; Bakker PJ; Curran D; Sahmoud T; Vermorken JB
    Eur J Cancer; 1997 Aug; 33(9):1513-5. PubMed ID: 9337698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teniposide (VM-26) in patients with advanced endometrial carcinoma. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Adcock L
    Am J Clin Oncol; 1991 Feb; 14(1):36-7. PubMed ID: 1987736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.